AI Engagement: Which Solutions Actually Drive Patient Use?

In the high-stakes arena of healthcare AI, the true measure of innovation extends far beyond technological prowess or capital raised. For Health Plan Executives and Employers/HR Buyers, the critical question isn’t merely “Does it work?” but rather, “Will patients actually use it?” This fundamental inquiry into engagement innovation separates theoretical promise from tangible clinical impact, revealing which AI solutions genuinely move the needle on population health outcomes.

Beyond the Hype: Defining Engagement Innovation in AI Health

The healthcare landscape is awash with AI solutions, yet many struggle with the most basic hurdle: patient adoption and sustained use. Our innovation index prioritizes real-world engagement because, as the relationship “engagement predicts outcomes” clearly illustrates, even the most sophisticated AI is inert without patient interaction. This perspective aligns with insights from thought leaders like Eric Topol, who consistently champions the need for technology that empowers patients and integrates seamlessly into their lives, rather than creating additional burdens. Similarly, Robert Wachter frequently highlights the complexities of integrating digital health tools into clinical workflows and patient behaviors, underscoring that usability and engagement are paramount for any meaningful impact. Eric Topol on patient empowerment through technology

Consider the contrast: while some AI health companies garner significant press coverage and venture capital, their impact wanes if patient adherence is low. Our index, therefore, scrutinizes evidence of sustained user interaction, completion rates, and behavioral activation. This is a departure from conventional metrics that might celebrate a novel algorithm or a substantial patent portfolio. Instead, we look for solutions that demonstrate efficacy through actual patient utilization, leading to verifiable clinical improvements.

Case Studies in Engagement: From Breakthroughs to Barriers

Several companies exemplify varying degrees of success in fostering patient engagement. Platforms like Omada Health and Noom have built their models heavily on behavioral science principles, leveraging AI to personalize interventions and maintain user motivation. Omada Health, for instance, focuses on chronic disease prevention and management, with AI-driven coaching and digital programs designed to sustain long-term engagement. Noom’s success in weight management is similarly tied to its ability to keep users active within its app, combining AI with human coaching to drive behavioral change. Omada Health clinical outcomes data

Livongo, now part of Teladoc Health, pioneered a highly engaged model for chronic condition management, particularly diabetes. Their approach integrated connected devices with AI-powered insights and human coaching, leading to impressive adherence rates and documented clinical improvements (CW3-DP-07). This success wasn’t just about the technology; it was about creating a user experience that felt supportive and actionable, directly addressing patient needs and motivations. Virta Health, focusing on type 2 diabetes reversal, similarly relies on a high-touch, digitally enabled model that combines physician supervision with health coaching and AI-driven dietary recommendations, achieving notable engagement and clinical outcomes.

The experience of Pear Therapeutics, a former pioneer in prescription digital therapeutics (PDTs), serves as a cautionary tale. While the company demonstrated the potential for FDA-cleared SaMD (Software as a Medical Device) to deliver clinical interventions with products designed to treat substance use disorder and insomnia, its commercialization path highlighted significant challenges. Despite robust clinical validation, Pear Therapeutics filed for Chapter 11 bankruptcy in April 2023, underscoring the difficulties of integrating novel digital therapies into traditional healthcare pathways and ensuring consistent patient adherence and reimbursement in real-world settings. Its FDA-cleared apps, reSET and reSET-O, were later acquired by PursueCare in December 2023 and relaunched in August 2024. The company’s trajectory underscores that even with robust clinical evidence and regulatory clearance, the “last mile” of patient engagement and viable business models remain formidable barriers for many “various low-engagement AI” solutions.

The distinction lies in understanding that AI is a tool, not a panacea. Its effectiveness is intrinsically linked to how well it integrates into human behavior and healthcare systems. Solutions that fail to account for the complexities of patient motivation, digital literacy, and clinical workflows often become “shelfware,” regardless of their underlying algorithmic sophistication.

Regulatory Context and Performance Benchmarks

The regulatory landscape for AI in healthcare, particularly the FDA SaMD Framework, emphasizes safety and efficacy. While clearances like 510(k) or De Novo classification validate a product’s clinical utility, they don’t explicitly guarantee real-world engagement or sustained impact. This is where organizations like KLAS Research, NCQA, and Rock Health play a crucial role. KLAS Research, through its in-depth vendor performance reports, offers insights into user satisfaction and adoption across various healthcare technologies. NCQA’s focus on quality measures and accreditation pushes for solutions that demonstrate value in patient care, implicitly valuing engagement that leads to better outcomes. Rock Health’s comprehensive digital health funding and market reports often highlight the importance of user experience and retention as key indicators of a company’s long-term viability.

Furthermore, adherence to standards like HIPAA is non-negotiable, ensuring patient data privacy and security. Yet, even with these foundational elements in place, the challenge of active and sustained patient participation persists. The most innovative AI health companies are those that master not only the technology but also the art of behavioral activation, translating regulatory compliance and clinical validation into practical, patient-centric solutions.

“The most potent AI in healthcare is not just intelligent; it is intimately understood and actively embraced by the patient it serves.”, AI Health Innovators Index Editorial Board

The Imperative of Engagement for Health Plan Executives and Employers

For Health Plan Executives and Employers/HR Buyers, investing in AI health solutions with proven engagement is paramount. Low engagement translates directly into wasted investment, ineffective care, and ultimately, a failure to improve population health or reduce costs. When evaluating potential partners, look beyond the initial buzz and delve into metrics that demonstrate sustained patient interaction and the resulting clinical outcomes. This includes published results from real-population testing, adherence rates, and evidence of behavioral change. CW3-DP-17, for example, illustrates the direct correlation between program engagement and specific health markers, providing tangible evidence of value. NCQA guidelines on digital health quality

The companies that will lead the charge in healthcare AI are not just those with the smartest algorithms, but those that have cracked the code on human behavior, integrating their AI seamlessly into the lives of the patients they aim to serve. Prioritizing engagement innovation ensures that investments yield tangible improvements in health outcomes, rather than simply adding another underutilized tool to the digital health arsenal.